Related Experiment Videos
Coagulation and anticoagulation in extracorporeal membrane oxygenation
1Department of Pediatrics, University of Graz, Austria. wolfgang.munteani@kfunigraz.ac.at
Artificial Organs
|November 24, 1999
Summary
Extracorporeal membrane oxygenation (ECMO) patients face hemostatic challenges due to foreign surfaces activating clotting. Improving ECMO anticoagulation and monitoring is key to reducing bleeding and thrombosis complications.
Area of Science:
- Biomedical Engineering
- Hematology
- Critical Care Medicine
Background:
- The hemostatic system is significantly challenged during extracorporeal membrane oxygenation (ECMO) due to the artificial surfaces of the extracorporeal circuit.
- Foreign surfaces activate platelets and the coagulation cascade, necessitating anticoagulation to prevent clot formation and platelet loss.
Purpose of the Study:
- To review the hemostatic problems encountered in ECMO.
- To discuss current anticoagulation strategies and monitoring methods.
- To explore potential improvements in managing hemostasis during ECMO.
Main Methods:
- Review of existing literature on hemostasis in ECMO.
- Analysis of common anticoagulation practices, primarily heparin and activated clotting time (ACT).
- Discussion of alternative and adjunctive therapeutic strategies.
Main Results:
- Bleeding and thrombosis are frequent, serious complications in ECMO patients, often exacerbated by pre-existing clotting disorders.
- Heparin and ACT monitoring are standard but may not fully mitigate hemostatic issues.
- Potential improvements lie in less thrombogenic materials, novel anticoagulants, platelet inhibitors, and protease inhibitors.
Conclusions:
- Optimizing hemostasis in ECMO requires a multifaceted approach.
- Combining improved circuit materials, advanced anticoagulation regimens, and diligent laboratory monitoring can reduce complications.
- While complete non-thrombogenicity is unlikely, significant improvements in patient outcomes are achievable.